This Article appeared in DSN | December 3, 2025
Read complete article on Drug Store News
Generic and biosimilar medicines created $467 billion in savings for patients and the overall healthcare system in 2024, according to The Association for Accessible Medicines’ 2024 U.S. Generic & Biosimilar Medicines Saving Report.
The report also noted that generics and biosimilars have saved more than $3.4 trillion in the last decade.
Despite the impressive savings, AAM president and CEO John Murphy III cautioned that generics and biosimilars are the only sector that consistently results in decreased spending across the U.S. healthcare ecosystem, but little is being done to infuse sustainability into the generic and biosimilar marketplace.
“The significant price deflation of the last 30 years can lead to unsustainable market conditions for generic drug manufacturers, dangerously impacting patient care and increasing the likelihood of shortages or even drugs leaving the market,” Murphy said. “Policymakers must streamline FDA processes, curb patent abuse and stop PBMs and Medicare policies from denying patient access and rollback harmful federal policies—including IRA price controls.”
Indeed, the generics industry faces myriad challenges, including the need to ensure a consistent supply of critical products, pressure on margins, deflation and the effect of potential tariffs.
To open a window on what the generics industry is facing and how it is committed to sprinting ahead, DSN called upon executives from generics firms to share their views on the state of the industry. Their answers reveal the perseverance and dedication of the industry and its ability to leave no stone unturned to serve their customers and patients.